Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557879 | 0.79 | PKM (0.36) | PTPN11LGMNHRH4PKMTACR2 | |
| SCHEMBL4557553 | 0.78 | TACR2 (0.40) | PTPN11LGMNALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5387983 | 0.76 | PTPN11 (0.37) | PTPN11LGMNALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9948445 | 0.75 | KMT2A (0.50) | HRH4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9086580 | 0.75 | TACR2 (0.44) | PTPN11LGMNALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10453209 | 0.75 | HRH4 (0.59) | HRH4 | |
| SCHEMBL128037 | 0.75 | HRH4 (0.59) | HRH4 | |
| SCHEMBL1396153 | 0.74 | PKM (0.58) | PKMALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL23593463 | 0.74 | PTPN11 (0.48) | PTPN11LGMNALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10609657 | 0.72 | CYP3A4 (0.51) | PTPN11ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | claimed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | claimed |
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6288228-B1 | DIAMINOTRIAZINE DERIVATIVES | ABBOTT LABORATORIES | 2001-09-11 | — | — | US | disclosed |
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | disclosed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |